(HAO) Haoxi Health Technology - Ratings and Ratios
Exchange: NASDAQ • Country: China • Currency: USD • Type: Common Stock • ISIN: US18383Q8539
HAO: Video Ads, Online Marketing Solutions, Healthcare Advertising Services
Haoxi Health Technology Limited, a China-based company, specializes in providing tailored online marketing solutions primarily to healthcare advertisers. Through its subsidiaries, the firm leverages major platforms like Toutiao, Douyin, WeChat, and Sina Weibo to deliver targeted advertising campaigns. Founded in 2018 and headquartered in Chaoyang, Haoxi Health Technology Limited is listed on the NASDAQ under the ticker symbol HAO, classified under the Advertising industry.
The companys advertising solutions encompass short video marketing and customized campaigns, designed to help clients acquire, convert, and retain consumers. By strategically planning, producing, and optimizing ads, Haoxi Health Technology Limited enhances the effectiveness of its clients marketing efforts across various digital platforms.
From a financial perspective, Haoxi Health Technology Limited has a market capitalization of $4.71 million, positioning it as a micro-cap company. Its price-to-earnings (P/E) ratio of 1.60 indicates undervaluation relative to its earnings. The price-to-book (P/B) ratio of 0.40 suggests the stock is trading below its book value, while the price-to-sales (P/S) ratio of 0.09 reflects a low valuation relative to revenue. The return on equity (RoE) stands at 19.52%, indicating positive profitability. However, the forward P/E ratio is 0.00, signaling a lack of analyst estimates for future earnings.
Over the next three months, Haoxi Health Technology Limiteds stock is expected to face headwinds, with its current price of $1.61 below the 20-day and 50-day Simple Moving Averages (SMAs) of $1.85 and $2.65, respectively. The 200-day SMA of $51.00 highlights a significant long-term decline. The Average True Range (ATR) of 0.28 indicates moderate volatility. While the companys low valuation metrics may attract value investors, the small market cap and lack of forward earnings estimates pose risks. The positive RoE, however, suggests underlying strength that could support recovery efforts.
Additional Sources for HAO Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
HAO Stock Overview
Market Cap in USD | 5m |
Sector | Communication Services |
Industry | Advertising Agencies |
GiC Sub-Industry | Advertising |
IPO / Inception | 2008-01-30 |
HAO Stock Ratings
Growth 5y | -53.0% |
Fundamental | 51.5% |
Dividend | 0.30% |
Rel. Strength Industry | -99.2 |
Analysts | - |
Fair Price Momentum | 1.65 USD |
Fair Price DCF | - |
HAO Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | 0.00% |
Payout Consistency | 1.0% |
HAO Growth Ratios
Growth Correlation 3m | -84% |
Growth Correlation 12m | -94.4% |
Growth Correlation 5y | -93.8% |
CAGR 5y | -97.85% |
CAGR/Max DD 5y | -0.99 |
Sharpe Ratio 12m | -2.38 |
Alpha | -98.59 |
Beta | -0.57 |
Volatility | 168.04% |
Current Volume | 4k |
Average Volume 20d | 1.1k |
As of March 18, 2025, the stock is trading at USD 1.66 with a total of 3,984 shares traded.
Over the past week, the price has changed by +2.88%, over one month by -14.53%, over three months by -49.80% and over the past year by -99.03%.
Partly, yes. Based on ValueRay Fundamental Analyses, Haoxi Health Technology (NASDAQ:HAO) is currently (March 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 51.50 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HAO as of March 2025 is 1.65. This means that HAO is currently overvalued and has a potential downside of -0.6%.
Haoxi Health Technology has no consensus analysts rating.
According to ValueRays Forecast Model, HAO Haoxi Health Technology will be worth about 1.8 in March 2026. The stock is currently trading at 1.66. This means that the stock has a potential upside of +7.23%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 1.8 | 7.2% |